RAS pathway mutation is an added‐value biomarker in pediatric Philadelphia‐negative B‐cell acute lymphoblastic leukemia with IKZF1 deletions-Reference-Cited by-同舟云学术

RAS pathway mutation is an added‐value biomarker in pediatric Philadelphia‐negative B‐cell acute lymphoblastic leukemia with IKZF1 deletions

Published:2021-02 Issue:4 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Huang Ying‐Jung¹,Liu Hsi‐Che²,Jaing Tang‐Her³⁴^ORCID,Wu Kang‐Hsi⁵,Wang Shih‐Chung⁶,Yen Hsiu‐Ju⁷^ORCID,Hsiao Chih‐Cheng⁴⁸,Chen Shih‐Hsiang³⁴^ORCID,Lin Pei‐Chin⁹^ORCID,Yeh Ting‐Chi²^ORCID,Sheen Jiunn‐Ming⁴⁸¹⁰,Chen Yu‐Chieh⁸,Chang Te‐Kau¹¹,Huang Fang‐Liang¹¹,Chao Yu‐Hua¹²^ORCID,Hou Jen‐Yin²^ORCID,Yang Chao‐Ping³,Lin Tung‐Huei¹,Shih Lee‐Yung¹⁴^ORCID

Affiliation:

1. Division of Hematology‐Oncology, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou Taoyuan Taiwan

2. Department of Hematology‐Oncology Mackay Children's Hospital and Mackay Medical College Taipei Taiwan

3. Department of Hematology‐Oncology Chang Gung Children's Hospital at Linkou Taoyuan Taiwan

4. College of Medicine Chang Gung University Taoyuan Taiwan

5. Division of Pediatric Hematology and Oncology China Medical University Children's Hospital Taichung Taiwan

6. Division of Pediatric Hematology‐Oncology Changhua Christian Children's Hospital Changhua Taiwan

7. Department of Pediatrics Taipei Veterans General Hospital Taipei Taiwan

8. Department of Pediatrics Chang Gung Memorial Hospital at Kaohsiung Kaohsiung Taiwan

9. Department of Pediatrics Kaohsiung Medical University Hospital Kaohsiung Taiwan

10. Department of Pediatrics Chang Gung Memorial Hospital at Chiayi Chiayi Taiwan

11. Department of Pediatrics Taichung Veterans General Hospital Taichung Taiwan

12. Department of Pediatrics Chung Shan Medical University Hospital Taichung Taiwan

Funder

Ministry of Health and Welfare

Ministry of Science and Technology, Taiwan

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28899

Reference26 articles.

1. The ikaros gene is required for the development of all lymphoid lineages

2. Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia

3. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

4. The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: An updated meta-analysis

5. Genetic Basis of Acute Lymphoblastic Leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis of pediatric BCP‐ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG‐2016 study;European Journal of Haematology;2024-06-07

2. IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia;Frontiers in Oncology;2024-04-03

3. The RAS‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group;Hematological Oncology;2024-04-02

4. Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1^plus and Day 15 MRD positivity;British Journal of Haematology;2024-03-13

5. Prevalence and prognostic significance of IKZF1 deletion in paediatric acute lymphoblastic leukemia: A systematic review and meta-analysis;Annals of Hematology;2023-05-08